系统性硬化症早期影像学进展:间质性肺病可预测长期死亡率
本研究基于硬皮病肺研究(SLS)I和II两个独立临床试验队列,采用计算机定量图像分析评估高分辨率CT上间质性肺病(ILD)范围的变化,随访长达12年(SLS I)和8年(SLS II)。提示影像学进展可作为系统性硬化症相关ILD(SSc-ILD)死亡风险的替代终点。
要点
- SLS I和II中ILD影像学范围12或24个月增加≥2%者长期生存显著更差。
- 影像学终点或可作为SSc-ILD死亡风险的替代指标。
核心结论
- 两个独立临床试验队列长期随访显示,12至24个月内ILD影像学进展可预测SSc患者长期死亡风险增加。
- 影像学终点可能作为SSc-ILD死亡率的替代指标。
研究设计与样本
- 基于硬皮病肺研究(SLS)I和II两个独立临床试验队列的长期随访分析。
- SLS I和II评估环磷酰胺(两研究均含)和霉酚酸酯(SLS II)治疗SSc-ILD的安全性与疗效。
- 通过高分辨率CT定量图像分析评估ILD范围随时间的变化。
- SLS I随访长达12年,SLS II随访长达8年。
- SLS I和II分别有82例和90例参与者有随访影像扫描并纳入分析。
主要发现
- 影像学进展的预测作用在治疗组和安慰剂组中均可见。
关键数值与推荐
- 影像学进展定义为12个月(SLS I)或24个月(SLS II)时ILD总定量影像学范围评分增加≥2%。
- 多变量Cox比例风险模型校正其他已知生存预测因素。
临床怎么用
- 对SSc-ILD患者,可在12至24个月内用高分辨率CT定量图像分析监测ILD影像学范围变化。
- 影像学范围增加≥2%提示长期死亡风险升高,可辅助风险分层与随访强度决策。
- 影像学进展可作为临床试验中评估治疗效果的替代终点参考。
局限性
- 分析仅纳入有随访影像扫描的参与者(SLS I 82例,SLS II 90例)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Radiographic end points commonly are included in therapeutic trials for systemic sclerosis (SSc)-interstitial lung disease (ILD); however, the relationship between these outcomes and long-term mortality is unclear. RESEARCH QUESTION: Do short-term changes in radiographic measures of ILD predict long-term survival in patients with SSc? STUDY DESIGN AND METHODS: The Scleroderma Lung Study (SLS) I and II evaluated the safety and efficacy of cyclophosphamide (in SLS I and II) and mycophenolate mofetil (in SLS II) for the treatment of SSc-ILD. Changes in the extent of ILD over time were assessed on high-resolution CT scans of the chest by quantitative image analysis, an approach that applies a computer-based algorithm to assess changes in the radiographic extent of ILD objectively. Participants subsequently were followed for up to 12 years (SLS I) and 8 years (SLS II). Cox proportional hazards models determined whether the change in the quantitative radiographic extent of ILD predicted survival, adjusting for other known predictors of survival. RESULTS: Among SLS I and II participants, 82 and 90 had follow-up imaging scans, respectively, and were included in the analysis. Participants in both trials who showed an increase in the total quantitative radiographic extent of ILD scores of ≥ 2% at 12 months (SLS I) or 24 months (SLS II) experienced significantly worse long-term survival than those with change scores of < 2% (P ≤ .01, log-rank test). In the multivariate Cox models, radiographic progression remained associated with worse long-term survival in SLS I (P = .089) and SLS II (P = .014). INTERPRETATION: Data from two independent clinical trial cohorts with extensive long-term follow-up demonstrated that radiographic progression of ILD over 12 to 24 months, in both treatment and placebo arms, can predict increased risk for long-term mortality in patients with SSc. These findings suggest that radiographic end points may serve as surrogates for mortality in SSc-ILD.
引用
- Volkmann ER, Tashkin DP, Roth MD, et al. Early Radiographic Progression of Scleroderma: Lung Disease Predicts Long-term Mortality. Chest. 2021. PMID: 34896093. doi:10.1016/j.chest.2021.11.033
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。